Literature DB >> 31256724

Effect of Intensive Blood Pressure Reduction on Left Ventricular Mass, Structure, Function, and Fibrosis in the SPRINT-HEART.

Bharathi Upadhya1, Michael V Rocco2, Nicholas M Pajewski3, Tim Morgan3, Joseph Blackshear4, William Greg Hundley1, Suzanne Oparil5, Elsayed Z Soliman6, Debbie L Cohen7, Craig A Hamilton8, Monique E Cho9, William J Kostis10, Vasilios Papademetriou11, Carlos J Rodriguez1, Dominic S Raj12, Ray Townsend7, Sujethra Vasu1, Sara Zamanian13, Dalane W Kitzman1.   

Abstract

In observational studies, left ventricular mass (LVM) and structure are strong predictors of mortality and cardiovascular events. However, the effect of hypertension treatment on LVM reduction and its relation to subsequent outcomes is unclear, particularly at lower blood pressure (BP) targets. In an ancillary study of SPRINT (Systolic Blood Pressure Intervention Trial), where participants were randomly assigned to intensive BP control (target systolic BP target <120 mm Hg) versus standard BP control (<140 mm Hg), cardiac magnetic resonance imaging was performed at baseline and 18-month follow-up to measure: LVM, volumes, ejection fraction, and native T1 mapping for myocardial fibrosis. At baseline, 337 participants were examined (age: 64±9 years, 45% women); 300 completed the 18-month exam (153 intensive control and 147 standard control). In the intensive versus standard BP control group at 18 months, there was no difference in change in LVM (mean±SE =-2.7±0.5 g versus -2.3±0.7 g; P=0.368), ejection fraction, or native T1 ( P=0.79), but there was a larger decrease in LVM/end-diastolic volume ratio (-0.04±0.01 versus -0.01±0.01; P=0.002) a measure of concentric LV remodeling. There were fewer cardiovascular events in the intensive control group, but no significant association between the reduced events and change in LVM or any other cardiac magnetic resonance imaging measure. In SPRINT-HEART, contrary to our hypothesis, there were no significant between-group differences in LVM, function, or myocardial T1 at 18-month follow-up. These results suggests that mediators other than these LV measures contribute to the improved cardiovascular outcomes with intensive BP control.

Entities:  

Keywords:  aging; blood pressure; hypertension; magnetic resonance imaging; ventricular remodeling

Year:  2019        PMID: 31256724      PMCID: PMC7098010          DOI: 10.1161/HYPERTENSIONAHA.119.13073

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  50 in total

1.  Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease.

Authors:  C G Brilla; R C Funck; H Rupp
Journal:  Circulation       Date:  2000-09-19       Impact factor: 29.690

2.  The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).

Authors:  Walter T Ambrosius; Kaycee M Sink; Capri G Foy; Dan R Berlowitz; Alfred K Cheung; William C Cushman; Lawrence J Fine; David C Goff; Karen C Johnson; Anthony A Killeen; Cora E Lewis; Suzanne Oparil; David M Reboussin; Michael V Rocco; Joni K Snyder; Jeff D Williamson; Jackson T Wright; Paul K Whelton
Journal:  Clin Trials       Date:  2014-06-05       Impact factor: 2.486

3.  Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance.

Authors:  Jennifer H Jordan; Ralph B D'Agostino; Craig A Hamilton; Sujethra Vasu; Michael E Hall; Dalane W Kitzman; Vinay Thohan; Julia A Lawrence; Leslie R Ellis; Timothy L Lash; W Gregory Hundley
Journal:  Circ Cardiovasc Imaging       Date:  2014-10-01       Impact factor: 7.792

4.  Association of echocardiographic left ventricular mass with body size, blood pressure and physical activity (the Framingham Study).

Authors:  D D Savage; D Levy; A L Dannenberg; R J Garrison; W P Castelli
Journal:  Am J Cardiol       Date:  1990-02-01       Impact factor: 2.778

5.  Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.

Authors:  J Mathew; P Sleight; E Lonn; D Johnstone; J Pogue; Q Yi; J Bosch; B Sussex; J Probstfield; S Yusuf
Journal:  Circulation       Date:  2001-10-02       Impact factor: 29.690

6.  Regional Adipose Distribution and its Relationship to Exercise Intolerance in Older Obese Patients Who Have Heart Failure With Preserved Ejection Fraction.

Authors:  Mark J Haykowsky; Barbara J Nicklas; Peter H Brubaker; W Gregory Hundley; Tina E Brinkley; Bharathi Upadhya; J Thomas Becton; Michael D Nelson; Haiying Chen; Dalane W Kitzman
Journal:  JACC Heart Fail       Date:  2018-07-11       Impact factor: 12.035

7.  Letter by Lewis et al Regarding Article, "Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial)".

Authors:  Gavin A Lewis; Erik B Schelbert; Christopher A Miller
Journal:  Circulation       Date:  2018-03-20       Impact factor: 29.690

8.  Left Ventricular Hypertrophy Regression During Antihypertensive Treatment in an Outpatient Clinic (the Campania Salute Network).

Authors:  Mai Tone Lønnebakken; Raffaele Izzo; Costantino Mancusi; Eva Gerdts; Maria Angela Losi; Grazia Canciello; Giuseppe Giugliano; Nicola De Luca; Bruno Trimarco; Giovanni de Simone
Journal:  J Am Heart Assoc       Date:  2017-03-08       Impact factor: 5.501

Review 9.  Oxidative stress and hypertension: Possibility of hypertension therapy with antioxidants.

Authors:  Azar Baradaran; Hamid Nasri; Mahmoud Rafieian-Kopaei
Journal:  J Res Med Sci       Date:  2014-04       Impact factor: 1.852

10.  Sustained Improvement of Arterial Stiffness and Blood Pressure after Long-Term Rosuvastatin Treatment in Patients with Inflammatory Joint Diseases: Results from the RORA-AS Study.

Authors:  Eirik Ikdahl; Silvia Rollefstad; Jonny Hisdal; Inge C Olsen; Terje R Pedersen; Tore K Kvien; Anne Grete Semb
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240

View more
  8 in total

1.  Effect of Lower Blood Pressure Goals on Left Ventricular Structure and Function in Patients With Subclinical Hypertensive Heart Disease.

Authors:  Phillip D Levy; Michael J Burla; Michael J Twiner; Alexander L Marinica; James J Mahn; Brian Reed; Aaron Brody; Robert Ehrman; Allie Brodsky; Yiying Zhang; Samar A Nasser; John M Flack
Journal:  Am J Hypertens       Date:  2020-09-10       Impact factor: 2.689

Review 2.  Hypertensive Heart Failure in Asia.

Authors:  Helsi Rismiati; Hae-Young Lee
Journal:  Pulse (Basel)       Date:  2021-10-11

3.  Risk-Based Intensive Blood Pressure Lowering and Prevention of Heart Failure: A SPRINT Post Hoc Analysis.

Authors:  Rebecca J Molsberry; Leah Rethy; Michael C Wang; Rupal C Mehta; Donald M Lloyd-Jones; Hongyan Ning; Cora E Lewis; Clyde W Yancy; Sanjiv J Shah; Sadiya S Khan
Journal:  Hypertension       Date:  2021-11-01       Impact factor: 10.190

4.  Association of Office and Ambulatory Blood Pressure with Left Ventricular Structure and Function in Hypertensive Patients.

Authors:  Zhuo Sang; Xianli Zeng; Xiaohui Yuan; Xiaolin Wang; Liancong Fu; Wenwen Zhuang
Journal:  Int J Gen Med       Date:  2022-05-04

5.  Global, regional, and national burden of hypertensive heart disease during 1990-2019: an analysis of the global burden of disease study 2019.

Authors:  Yunyan Lu; Tian Lan
Journal:  BMC Public Health       Date:  2022-04-27       Impact factor: 4.135

6.  Cardiac sympathetic dysfunction in left ventricular hypertrophy caused by arterial hypertension and degenerative aortic stenosis.

Authors:  Riccardo Liga; Alessia Gimelli; Marco De Carlo; Paolo Marzullo; Roberto Pedrinelli; Anna Sonia Petronio
Journal:  J Nucl Cardiol       Date:  2020-07-01       Impact factor: 5.952

7.  Effect of Intensive Blood Pressure Control on Aortic Stiffness in the SPRINT-HEART.

Authors:  Bharathi Upadhya; Nicholas M Pajewski; Michael V Rocco; W Gregory Hundley; Gerard Aurigemma; Craig A Hamilton; Jeffrey T Bates; Jiang He; Jing Chen; Michel Chonchol; Steve P Glasser; Adriana M Hung; Roberto Pisoni; Henry Punzi; Mark A Supiano; Robert Toto; Addison Taylor; Dalane W Kitzman
Journal:  Hypertension       Date:  2021-03-29       Impact factor: 10.190

Review 8.  Heart Failure Primary Prevention: What Does SPRINT Add?: Recent Advances in Hypertension.

Authors:  Kirsten Raby; Michael Rocco; Suzanne Oparil; Olivia N Gilbert; Bharathi Upadhya
Journal:  Hypertension       Date:  2021-04-05       Impact factor: 9.897

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.